We are live on
!
Find out more
BI
BVF Inc Portfolio holdings
AUM
$3.91B
1-Year Est. Return
304.52%
This Fund
S&P 500
This Quarter
Est. Return
+14.28%
1 Year Est. Return
+304.52%
3 Year Est. Return
+591.72%
5 Year Est. Return
+1,391.92%
10 Year Est. Return
+28,184.58%
AUM
$3.14B
AUM Growth
+$168M
(+5.7%)
Cap. Flow
-$21.7M
Cap. Flow
% of AUM
-0.69%
Top 10 Holdings %
Top 10 Hldgs %
62.21%
Holding
45
New
4
Increased
10
Reduced
11
Closed
4
Avg Time Held
13
quarters
Top 10 Avg Time Held
5.7
quarters
Top 20 Avg Time Held
8.4
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alkermes
ALKS
|
+$62M |
| 2 |
Nektar Therapeutics
NKTR
|
+$56.9M |
| 3 |
Disc Medicine
IRON
|
+$43.2M |
| 4 |
Sutro Biopharma
STRO
|
+$22.6M |
| 5 |
Anteris Technologies
AVR
|
+$17.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abivax
ABVX
|
+$68.5M |
| 2 |
MoonLake Immunotherapeutics
MLTX
|
+$62.1M |
| 3 |
Revolution Medicines
RVMD
|
+$50.5M |
| 4 |
Repare Therapeutics
RPTX
|
+$26.9M |
| 5 |
4D Molecular Therapeutics
FDMT
|
+$15.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.92% |
| 2 | Miscellaneous | 0.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
26
Sutro Biopharma
STRO
$183M
| $31.2M | 0.99% |
+1,251,788
| New | +$22.6M |
2026 Q1
0 quarters
|
|
27
Foghorn Therapeutics
FHTX
$110M
| $27.9M | 0.89% |
5,842,000
+540,000
| +10% | +$2.96M |
2024 Q2
7 quarters
|
|
|
28
4D Molecular Therapeutics
FDMT
$683M
| $26.8M | 0.85% |
2,879,289
-1,750,000
| -38% | -$15.2M |
2020 Q4
21 quarters
|
|
29
Invivyd
IVVD
$190M
| $25.4M | 0.81% |
19,525,000
| – | – |
2025 Q4
1 quarter
|
|
30
Avalo Therapeutics
AVTX
$644M
| $24.4M | 0.78% |
1,632,845
+277,588
| +20% | +$4.34M |
2024 Q3
6 quarters
|
|
31
Eledon Pharmaceuticals
ELDN
$190M
| $19.4M | 0.62% |
6,293,282
| – | – |
2019 Q2
27 quarters
|
|
|
32
Anteris Technologies
AVR
$629M
| $16.6M | 0.53% |
+3,000,000
| New | +$17.2M |
2026 Q1
0 quarters
|
|
33
X4 Pharmaceuticals
XFOR
$258M
| $9.23M | 0.29% |
2,233,742
| – | – |
2025 Q3
2 quarters
|
|
34
Immunic
IMUX
$94M
| $8.49M | 0.27% |
765,297
| – | – |
2024 Q1
8 quarters
|
|
35
OnKure Therapeutics
OKUR
$95M
| $8.19M | 0.26% |
+1,978,972
| New | +$6.11M |
2026 Q1
0 quarters
|
|
36
TScan Therapeutics
TCRX
$14.7M
| $5.62M | 0.18% |
5,564,290
+338,216
| +6% | +$361K |
2023 Q2
11 quarters
|
|
37
ImageneBio Inc
IMA
$48.1M
| $5.55M | 0.18% |
1,110,002
+307,900
| +38% | +$2M |
2021 Q1
20 quarters
|
|
38
Tenax Therapeutics
TENX
$59.9M
| $5.43M | 0.17% |
339,549
| – | – |
2024 Q3
6 quarters
|
|
39
Molecular Partners
MOLN
$141M
| $5.36M | 0.17% |
1,353,968
| – | – |
2021 Q3
18 quarters
|
|
40
Inventiva
IVA
$678M
| $3.81M | 0.12% |
686,040
| – | – |
2021 Q1
20 quarters
|
|
41
enGene Therapeutics Warrants
ENGNW
| $2.49M | 0.08% |
945,402
| – | – |
2023 Q4
9 quarters
|
|
|
42
Abivax
ABVX
$7.52B
| – | – |
-508,031
| Closed | -$68.5M | – |
|
43
Axsome Therapeutics
AXSM
$8.19B
| – | – |
-45,757
| Closed | -$8.36M | – |
|
44
PepGen
PEPG
$173M
| – | – |
-1,915,000
| Closed | -$12.5M | – |
|
|
45
DELISTED
Repare Therapeutics
RPTX
| – | – |
-10,333,600
| Closed | -$26.9M | – |
|
Similar funds
LFCM
DCM
LNC
GL
AC
FFGIM
AIM
LCM
BVF Inc's Q1 2026 Portfolio in Review
As of Q1 2026, BVF Inc held 45 positions worth $3.14B, up 5.7% from $2.97B the previous quarter. Its ten largest holdings account for 62% of the portfolio.
BVF Inc's Q1 2026 filing shows 4 new, 10 increased, 11 reduced and 4 closed positions. Its largest new stake was Alkermes: 2,000,000 shares worth $70.7M. The largest sale was Abivax, an estimated $68.5M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.
- BVF Inc's largest Q1 2026 buy was Alkermes: 2,000,000 shares worth $70.7M.
- BVF Inc added most to Nektar Therapeutics in Q1 2026, an estimated $56.9M increase.
- BVF Inc's biggest Q1 2026 reduction was MoonLake Immunotherapeutics, cutting an estimated $62.1M.
- BVF Inc fully exited Abivax in Q1 2026, selling an estimated $68.5M.
- BVF Inc's ten largest holdings make up 62% of its $3.14B portfolio in Q1 2026.
- BVF Inc opened 4 new positions and closed 4 in Q1 2026.
- BVF Inc's portfolio value rose 5.7% quarter-over-quarter to $3.14B.
Based on BVF Inc's 13F filing for Q1 2026, filed 15 May 2026.